RT Book, Section
A1 Honaker, Jeremy S.
A1 Korman, Neil J.
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161344313
T1 Cytotoxic and Antimetabolic Agents
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK dermatology.mhmedical.com/content.aspx?aid=1161344313
RD 2024/04/19
AB AT-A-GLANCECytotoxic  and  antimetabolic  agents  are  used  in  dermatology  to  treat  serious,  life-threatening,  and  recalcitrant  disease.Methotrexate  and  azathioprine  are  commonly  used  in  dermatology  whereas  thioguanine,  hydroxyurea,  cyclophosphamide,  chlorambucil,  and  liposomal  doxorubicin  are  occasionally  used.Methotrexate  is  U.S.  Food  and  Drug  Administration  (FDA)  approved  for  treatment  of  psoriasis  and  advanced  mycosis  fungoides,  whereas  cyclophosphamide  is  FDA  approved  for  advanced  mycosis  fungoides  only,  and  liposomal  doxorubicin  is  approved  for  AIDS-related  Kaposi  sarcoma;  other  uses  of  the  agent  in  this  chapter  occur  on  an  “off-label”  basis.Cytotoxic  and  antimetabolic  agents  act  through  inhibition  and/or  interruption  of  the  cell  cycle.Side  effects  and  complications  with  these  potentially  dangerous  medications  are  numerous,  and  close  clinical  followup  and  laboratory  evaluation  is  necessary.Cytotoxic  agents  used  in  dermatology,  as  well  as  those  initiated  for  other  purposes,  may  yield  distinctive  cutaneous  eruptions  and  cutaneous  sequelae.